Affiliation:
1. Department of Surgery, Division of Otolaryngology‐Head and Neck Surgery University of Wisconsin Madison Wisconsin USA
2. Department of Integrative Biology University of Wisconsin Madison Wisconsin USA
Abstract
Objectives and hypothesisVocal dysfunction, including hypophonia, in Parkinson disease (PD) manifests in the prodromal period and significantly impacts an individual's quality of life. Data from human studies suggest that pathology leading to vocal deficits may be structurally related to the larynx and its function. The Pink1−/− rat is a translational model used to study pathogenesis in the context of early‐stage mitochondrial dysfunction. The primary objective of this work was to identify differentially expressed genes in the thyroarytenoid muscle and examine the dysregulated biological pathways in the female rat.MethodsRNA sequencing was used to determine thyroarytenoid (TA) muscle gene expression in adult female Pink1−/− rats compared with controls. A bioinformatic approach and the ENRICHR gene analysis tool were used to compare the sequencing dataset with biological pathways and processes, disease relationships, and drug‐repurposing compounds. Weighted Gene Co‐expression Network Analysis was used to construct biological network modules. The data were compared with a previously published dataset in male rats.ResultsSignificant upregulated pathways in female Pink1−/− rats included fatty acid oxidation and muscle contraction, synaptic transmission, and neuromuscular processes. Downregulated pathways included anterograde transsynaptic signaling, chemical synaptic transmission, and ion release. Several drug treatment options including cetuximab, fluoxetine, and resveratrol are hypothesized to reverse observed genetic dysregulation.ConclusionsData presented here are useful for identifying biological pathways that may underlie the mechanisms of peripheral dysfunction including neuromuscular synaptic transmission to the TA muscle. These experimental biomarkers have the potential to be targeted as sites for improving the treatment for hypophonia in early‐stage PD.Level of EvidenceNA Laryngoscope, 133:3412–3421, 2023
Funder
National Institutes of Health
National Center for Advancing Translational Sciences
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献